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Abstract
Background:  Animal data show that decreased activity of placental 11-beta-hydroxysteroid
dehydrogenase type 2 (11β-HSD2), which potently inactivates glucocorticoids (e.g. cortisol) to
inert forms (cortisone), allows increased access of maternal glucocorticoids to the fetus and
'programs' hypertension. Data in humans are limited. We examined in humans the association
between venous umbilical cord blood glucocorticoids, a potential marker for placental 11β-HSD2
enzyme activity, and blood pressure at age 3 years.
Methods: Among 286 newborns in Project Viva, a prospective pre-birth cohort study based in
eastern Massachusetts, we measured cortisol (F) and cortisone (E) in venous cord blood and used
the ratio of F/E as a marker for placental 11β-HSD2 activity. We measured blood pressure (BP)
when the offspring reached age 3 years. Using mixed effects regression models to control for BP
measurement conditions, maternal and child characteristics, we examined the association between
the F/E ratio and child BP.
Results: At age 3 years, each unit increase in the F/E ratio was associated with a 1.6 mm Hg
increase in systolic BP (95% CI 0.0 to 3.1). The F/E ratio was not associated with diastolic blood
pressure or birth weight for gestational age z-score.
Conclusion: A higher F/E ratio in umbilical venous cord blood, likely reflecting reduced placental
11β-HSD2 activity, was associated with higher systolic blood pressure at age 3 years. Our data
suggest that increased fetal exposure to active maternal glucocorticoids may program later systolic
blood pressure.
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Background
Many observational studies have demonstrated an inverse
association between birth weight and blood pressure
(BP), raising the intriguing possibility that lifelong hyper-
tension might be programmed in utero [1]. The mecha-
nisms underlying this association remain unclear.
One plausible hypothesis, based on animal data, pro-
poses that a low protein diet during pregnancy leads to
increased fetal glucocorticoid exposure, permanently pro-
gramming both lower birth weight and elevated BP in off-
spring [2]. Studies in humans have not found a consistent
association between maternal protein intake and off-
spring blood pressure [3-6], but few studies have exam-
ined whether fetal glucocorticoid exposure might
program offspring BP.
Experiments in rats have shown that maternal treatment
during pregnancy with the synthetic glucocorticoid dex-
amethasone, which freely crosses the placenta, is associ-
ated with lower birth weight and raised BP in the offspring
[7]. Protection from exposure to maternal physiological
glucocorticoids is mediated by a placental enzyme, 11-
beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2),
which converts active glucocorticoid (corticosterone in
rats, cortisol in humans) into inert 11-keto forms [7]. The
'placental barrier' function of 11β-HSD2 is important
because circulating maternal cortisol freely crosses the pla-
centa.
A relative deficiency of placental 11β-HSD2 might allow
increased access of maternal glucocorticoids to the fetus,
retarding growth and programming responses leading to
later hypertension, as suggested by studies in rats and
mice [7-9]. Humans who are homozygous for the gene
encoding 11β-HSD2, resulting in little or no enzyme
activity, show much lower birth weight than their unaf-
fected (mainly heterozygous) siblings [10]. Limited data
suggest that heterozygous carriers may have a milder phe-
notype indistinguishable from essential hypertension,
though dissecting placental from offspring renal effects is
problematic [11].
We hypothesized that a higher ratio of cortisol to corti-
sone in umbilical venous cord blood, reflecting decreased
11β-HSD2 activity, would be associated with lower birth
weight and raised blood pressure in childhood. We exam-
ined this hypothesis within Project Viva, a longitudinal
cohort of pregnant women and their offspring.
Methods
Subjects
We recruited women with a singleton pregnancy from
April 1999 to July 2002 at eight obstetric offices in the
Boston, Massachusetts, USA area [12]. Women were
study-eligible if they entered prenatal care before 22
weeks of gestation, planned ongoing obstetric care at an
enrollment site, and were able to answer questionnaires in
English. We collected sociodemographic and medical data
through in-person interviews, self-administered question-
naires and hospital and ambulatory medical records.
Human Subjects Committees of Harvard Pilgrim Health
Care, Brigham and Women's Hospital, and Beth Israel
Deaconess Medical Center approved study protocols. All
participants gave informed consent [12].
We previously described study population, enrollment
and follow up procedures [12]. Of 657 infants with cord
blood stored at 4°C for less than 30 hours, 362 infants
were eligible for this analysis (mothers consented to
enroll their infants into the study and completed a
research visit including blood pressure at age 6 months).
Of the 362 eligible infants, 286 (79%) returned for a 3-
year blood pressure measurement. Therefore, we based
our analyses on 286 children with 3-year blood pressure.
Umbilical cord blood glucocorticoids
At the time of delivery, using a needle and syringe tech-
nique, a midwife or obstetrician collected cord venous
blood. Because research technicians were unable to be
present at every delivery, delivery room staff refrigerated
the specimen immediately after collection for a period of
up to 30 hours (median: 13 hours). A research technician
then separated the specimen into aliquots of serum, red
blood cells, and white blood cells for storage at -70°C
until analysis. We performed a small validation study to
ensure that refrigeration of samples for less than 30 hours
did not lead to degradation of glucocorticoid levels. We
collected blood samples from 11 pregnant women and
used three different methods of storage and processing. In
method A (the gold standard), blood was drawn into
room temperature heparinized glass tubes, spun at room
temperature immediately, and the plasma was frozen at -
20°C for 24 hours before being transported to a storage
site and stored at -80°C for 1–6 months. In method B,
blood was treated similarly except that after being drawn
it was refrigerated at 4°C for 4 hours, and in method C for
24 hours. We found that within-person cortisol levels did
not significantly differ by cortisol processing protocol.
Comparing methods A and B, the mean within-person
difference in cortisol was 22.1 nmol/liter (95%CI -129.7
to 173.8, p = 0.76). Comparing methods A and C, the
mean within-person difference in cortisol was 60.7 nmol/
liter (95% CI -80.0 to 204.2, p = 0.36).
Cortisol and cortisone were quantified in duplicate in
venous cord plasma by validated direct radioimmu-
noassay techniques [13,14]. Concentrations of cortisol
and cortisone were determined using a radioimmu-
noassay kit for cortisol (MP Biomedicals, UK) and corti-BMC Medicine 2008, 6:25 http://www.biomedcentral.com/1741-7015/6/25
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sone (Immunovation Ltd, Southampton, UK) [15]. The
intra-assay coefficients of variation were 5.6% and 5.2%
for cortisol and cortisone respectively.
We used the mean of duplicate cortisol and cortisone
assays to calculate our primary exposure, the ratio of cor-
tisol/cortisone in umbilical venous blood, which corre-
lates well (r = 0.5) with direct measures of 11β-HSD2
activity using placental tissue homogenates [16].
Blood pressure and anthropometric measurements
At the 3-year visit, trained research assistants measured
each child's blood pressure (BP) up to five times, at 1-
minute intervals, using a Dinamap Pro 100 or Pro 200
(Critikon Inc., Tampa, FL, USA) automated blood pres-
sure monitor. We recorded the conditions of measure-
ment as previously described [3], including room
temperature, activity state of the child (crying, quiet
awake, active awake), cuff size (infant, child, small adult),
appendage used for BP measurement (left arm, right arm,
calf), and child position (semi-reclining, seated, stand-
ing). The majority of children, 255 out of 286 (89%), had
five blood pressure measurements (mean 4.8), and 87%
of measurements were taken when the child was in a
quiet, awake state. We defined our primary endpoint to be
child systolic BP, because of its validity of measurement
with an automated device [17]. We examined diastolic BP
as a secondary outcome.
We measured child weight with a digital scale, and height
using a stadiometer (Shorr Productions, Olney, MD,
USA). We calculated a continuous measure of sex-specific
birth weight for gestational age z-score (fetal growth)
based on published US reference standards [18]. We com-
puted gestational age at birth as the number of days
between the first day of last menstrual period and the
delivery date and confirmed by ultrasound fetal measure-
ments at 16–20 weeks. For date discrepancies of more
than 10 days, we used the ultrasound-based gestational
age.
Statistical methods
To assess multivariable associations between cord gluco-
corticoids and offspring BP, we used mixed effect regres-
sion models, incorporating each of the up to five BP
measurements per child as repeated outcome measures
[19]. In contrast to standard ordinary least squares analy-
sis, mixed effect models weight subjects based on the
number of measurements and their variability, and thus
result in appropriate standard errors. In our baseline crude
model, we included only BP measurement conditions to
reduce measurement error in child BP. Crude models
stratified by gender showed similar associations among
males and females; therefore we combined males and
females in our models, adjusting for gender. In our multi-
variable model, we added gestational age at birth, child
age, gender, attained length and weight, and maternal race
and income [18]. Potential confounders that did not
change our effect estimates included maternal age, pre-
pregnancy body mass index, maternal height, gravidity,
pregnancy weight gain, third-trimester BP, induced deliv-
ery, Caesarean section, Apgar score, smoking status prior
to pregnancy, education level, and marital status. There-
fore, we excluded these variables from our final models.
We conducted all data analyses using SAS version 9.1 (SAS
Institute Inc., Cary, NC, USA).
Results
Participant characteristics are shown in Table 1. Most
mothers had a relatively high level of income and educa-
tion. Mean venous cord cortisol was 343.9 nmol/liter
(74.5–1042.9, 1st to 99th percentile). Mean venous cord
cortisone was 242.7 nmol/liter (106.3–484.0, 1st to 99th
percentile). Mean F/E ratio was 1.4 (0.5–3.8, 1st to 99th
percentile). The Pearson correlation of the F/E ratio with
cortisol was 0.8, and with cortisone was -0.1. The correla-
tion of F/E ratio with birth weight for gestational age z-
score was 0.02, and with gestational age at birth was 0.1.
Mean systolic blood pressure was 93.3 mm Hg at age 3
years. Mean diastolic blood pressure was 58.9 mm Hg.
Compared with the 657 mother-offspring pairs with cord
blood, mothers included in our analyses had a slightly
higher level of education (69% vs 62% completed a col-
lege or graduate degree) and had a higher household
income (60% vs 54% reported income of more than
$70,000 per year). Mean birth weight was similar among
infants included in our analyses compared with all eligi-
ble infants (3545 g vs 3529 g). Child systolic and diastolic
blood pressure, length and weight were similar among
included and eligible children.
Bivariate analyses showing systolic BP as a function of F/E
ratio are shown in Figure 1. In multivariable analyses,
each one unit increment in F/E ratio was associated with a
1.6 mm Hg (95% CI 0.0 to 3.1, p = 0.05) increment in
systolic BP at age 3 years (Table 2). The direction of this
effect estimate at age 3 years was consistent with our
hypothesis that higher F/E  ratio, reflecting lower 11β-
HSD2 activity, would be associated with higher blood
pressure. The effect estimate for diastolic BP at 3 years was
0.8 mm Hg (95% CI -0.4 to 2.0), adjusted for other cov-
ariates.
In unadjusted analyses, the F/E ratio was not associated
with birth weight; the effect estimate for birth weight was
47.1 g per one unit increment in the F/E ratio estimating
placental 11β-HSD2 activity (95% CI -42.9 to 137.1).
After adjustment for gestational age and sex, there was no
association between F/E ratio and birth weight (-0.2 g forBMC Medicine 2008, 6:25 http://www.biomedcentral.com/1741-7015/6/25
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each one unit increment in F/E ratio, 95% CI -76.1 to
75.7). After additional adjustment for maternal age, BMI,
race, income, and smoking status, the effect estimate was
-12.1 g per unit increment in F/E ratio (95% CI -87.0 to
62.8). In unadjusted analyses, the effect estimate for the
association between F/E ratio and gestational age at birth
was 0.2 weeks per one unit increment in the F/E ratio
(95% CI -0.0 to 0.5, p = 0.05). Additional adjustment for
maternal age, BMI, race, income, and smoking status did
not materially change the effect estimate (0.2 weeks, 95%
CI -0.05 to 0.5, p = 0.11).
Discussion
Our study is the first in humans to examine the relation-
ship between umbilical cord concentrations of glucocorti-
coids and offspring blood pressure. We found that a one
unit increment in F/E ratio, a proxy for reduced placental
11β-HSD2 activity, was associated with a 1.6 mm Hg
higher systolic BP at 3 years of age. Although this effect
estimate may appear to be small, a shift of this magnitude
in the mean population blood pressure could result in a
clinically meaningful difference in the prevalence of
hypertension. A meta-analysis of 1 million adults esti-
Table 1: Cord blood glucocorticoids and other characteristics of 286 participants with 3-year blood pressure.
n Mean (SD) or %
Maternal characteristics at enrollment
Age (years) 286 32.2 (4.9)
Pre-pregnancy BMI (kg/m2) 284 24.6 (5.1)
Race/ethnicity (%)
White 204 71%
Black 31 11%
Hispanic 20 7%
Asian 13 5%
Other 18 6%
Marital status (%)
Married 238 83%
Partner 26 9%
Other 22 8%
Education (%)
High school or less 17 6%
Less than 4 years of college 73 26%
4 years of college 100 35%
Graduate degree 96 34%
Annual household income (%)
<$20 000 31 %
$20 000–$40 000 30 10%
$40 000–$70 000 65 23%
>$70 000 173 61%
Missing 15 5%
Smoked 3 months prior to pregnancy (%) 23 8%
Pregnancy weight gain (kg) 283 15.6 (5.5)
3rd trimester systolic BP (mm Hg) 285 110.9 (8.3)
Spontaneous delivery (vs induced) 186 65%
Caesarean section (vs vaginal delivery) 47 16%
Child characteristics
Male (%) 146 51%
Birth weight (g) 286 3545 (501)
Birth weight for gestational age z-value (units) 286 0.2 (0.9)
Gestational age (weeks) 286 39.7 (1.3)
Cortisol (nmol/liter) 286 343.9 (209.3)
Cortisone (nmol/liter) 286 242.7 (81.3)
Cortisol/cortisone ratio (units) 286 1.4 (0.6)
Systolic BP at age 3 years (mm Hg) 286 93.3 (10.2)
Diastolic BP at age 3 years (mm Hg) 286 58.9 (8.0)
Weight at age 3 years (kg) 286 15.8 (2.6)
Height at age 3 years (cm) 286 97.6 (4.6)
BP, blood pressure.BMC Medicine 2008, 6:25 http://www.biomedcentral.com/1741-7015/6/25
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mated that a 2 mm Hg reduction in systolic blood pres-
sure could result in a 10% decrease in mortality from
stroke, and a 7% decrease in mortality from ischemic
heart disease [20]. We did not find an association between
F/E ratio and fetal growth, suggesting that lower activity
levels of 11β-HSD2 might program higher offspring
blood pressure without restricting overall fetal growth.
Our finding is consistent with data in animals showing
that decreased placental 11β-HSD2 activity programs
higher offspring blood pressure. Rats and sheep treated
during pregnancy with the glucocorticoid dexametha-
sone, a relatively poor substrate for 11β-HSD2, have off-
spring with reduced birth weight and elevated blood
pressure in offspring [7]. Pregnant rats given an 11β-
HSD2 inhibitor (carbenoxolone) have offspring with
lower birth weight and raised blood pressure [8]. In addi-
tion, pregnant rats fed a low protein diet have been shown
to have both decreased placental 11β-HSD2 activity and
higher offspring BP [2]. Within Project Viva, we did not
find a relationship either between protein intake and
infant BP [3] or between protein intake and F/E ratio (data
not shown).
No human studies have directly examined the relation-
ship of placental 11β-HSD2 activity or cord glucocorti-
coid levels with later blood pressure. A few studies in
humans have examined the effect of prenatal exogenous
steroid administration on later blood pressure. In one
observational study, preterm infants exposed to antenatal
betamethasone had higher systolic BP and diastolic BP in
adolescence than unexposed infants [21]. However, fol-
low-up data from two randomized controlled trials using
two doses of prenatal betamethasone found that prenatal
betamethasone use either did not affect offspring blood
pressure [22,23], or was associated with a lower systolic
blood pressure in offspring [24]. It is possible that the
effects of 11β-HSD2 activity could differ among preterm
and term infants. Several [16,25,26], but not all [27-29],
studies suggest that human placental 11β-HSD2 expres-
sion or activity rises with increasing gestational age until
term; our data suggested a direct correlation between F/E
ratio and gestational age at birth, although the effect esti-
mates did not reach statistical significance. Preterm
infants may also be predisposed to higher blood pressures
in later life for other reasons [30]. Our study excluded
infants with a gestational age of less than 33 weeks and
may therefore be more generalizable than prior studies
focusing on preterm infants.
In animals, lower placental 11β-HSD2 activity is associ-
ated with lower birth weight [8]. In humans, similar asso-
Table 2: Multivariable mixed effect models showing change in 3-year child BP per unit increment in venous cord F/E ratio.
Change in child BP (mm Hg) per one unit increment in F/E ratio (95% CI)
Models* Systolic BP Diastolic BP
Model 1: F/E ratio (unit increment) 1.2 (-0.4 to 2.7)
p = 0.14
0.7 (-0.5, 1.8)
p = 0.27
Model 2: Model 1 + infant sex, gestational age at birth, age, 3 year 
weight, length, maternal race/ethnicity, income
1.6 (0.0 to 3.1)
p = 0.05
0.8 (-0.4, 2.0)
p = 0.20
Data from 286 mother-offspring pairs within Project Viva.
*All models were adjusted for blood pressure measurement order, cuff size, appendage, position, state, and machine model. BP, blood pressure; F/
E, cortisol/cortisone ratio in venous cord blood.
Systolic blood pressure (BP) at age 3 years as a function of  cortisol/cortisone (F/E) ratio Figure 1
Systolic blood pressure (BP) at age 3 years as a func-
tion of cortisol/cortisone (F/E) ratio. Bivariable regres-
sion line (solid line), unadjusted for covariates, and its 95% 
confidence limits (dotted lines) are shown.BMC Medicine 2008, 6:25 http://www.biomedcentral.com/1741-7015/6/25
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ciations have been shown in preterm infants [16,31].
Among term infants, two studies did not find an associa-
tion between 11β-HSD2 activity and birth weight [32,33].
One study found that among asthmatic pregnant women
with a female fetus, lower birth weight was associated
with reduced placental 11β-HSD2 activity [34]; this asso-
ciation was not present among women pregnant with a
male fetus [34], suggesting that there may be sex-specific
differences in regulation of 11β-HSD2 activity. Our data
(mean gestational age 39.7 weeks) showed little associa-
tion between the F/E ratio and fetal growth, suggesting
that a relative deficiency in placental 11β-HSD2 activity
might program higher offspring blood pressure without
affecting birth weight. Stratification by child gender made
no difference to our analyses. Because birth weight has
many determinants, it is not surprising that physiologic
programming of blood pressure might occur without
affecting birth weight [35].
Our results must be interpreted with caution, because we
used F/E ratio in venous cord blood as a proxy for placen-
tal 11β-HSD2 activity rather than directly measuring
enzyme activity. Glucocorticoids in the human fetal circu-
lation may originate from the fetal adrenal gland, or from
maternal cortisol, which freely crosses the placenta. Data
show that 75–100% of cord blood cortisone originates
from placental metabolism of maternal cortisol [36]. Cor-
tisol levels in venous umbilical cord blood may be
affected by increased production of cortisol by fetal adre-
nal glands at term, as well as maternal or fetal stress and
other factors [37]. Adjustment for mode of delivery and
induction of labor made no difference to our estimates;
other variables relating to labor and delivery, such as
duration of labor, or the use of instrumentation were not
available for these analyses. Prior studies have not found
an effect of labor on 11β-HSD2 mRNA or activity levels
[29,38].
Among healthy term infants, the ratio of cortisol/corti-
sone in umbilical venous cord blood appears to correlate
well with direct measures of placental 11β-HSD2 activity
using placental tissue homogenates [16]. A study that
measured placental cortisol metabolism using a similar
venous cord ratio, E/(E+F), was not improved by creation
of an 11β-HSD2 activity index incorporating arterial cord
glucocorticoid measurements [39], which presumably
reflect the fetal adrenal contribution (Pearson correlation
between E/(E+F) and F/E was 0.9 using our data). The
cord F/E ratio could also be affected by the activity of
either placental 11β-hydroxysteroid dehydrogenase type 1
enzyme (11β-HSD1) or fetal 11β-HSD2. 11β-HSD1, an
enzyme isoform that can convert cortisone to cortisol, has
been detected in human perfused placenta [40], and pla-
cental 11β-HSD1 activity levels may increase during gesta-
tion [41]. However, studies suggest that type 2 enzymatic
activity predominates during pregnancy [27,42], with one
study reporting no detectable 11β-HSD1 activity [43].
Several fetal tissues express 11β-HSD2 until mid-gestation
[44]. Dy et al. recently reported that among term infants
born with intrauterine growth restriction, the ratio of cor-
tisone to cortisol in the umbilical artery was lower than in
the umbilical vein, suggesting either attenuated fetal 11β-
HSD2 activity, or reduced fetal glucocorticoid clearance
[45]. Term infants with a birth weight appropriate for ges-
tational age showed no difference in cortisone to cortisol
ratio between the umbilical artery and vein [45]. Since
most 11β-HSD2 expression is lost from the fetus by term
(at least in rodents and probably in humans) we think this
is unlikely to have contributed to levels of cortisol and
cortisone in cord blood, emphasizing the placental contri-
bution.
Among infants born preterm or small for gestational age,
the F/E ratio may not be a valid proxy for placental 11β-
HSD2 activity. A study of preterm infants born at less than
32 weeks gestational age was unable to detect a correla-
tion between venous cord blood glucocorticoid concen-
trations and placental 11β-HSD2 activity [31]. A recent
study reported that compared with term infants with a
birth weight appropriate for gestational age, infants with
intrauterine growth restriction had reduced placental
homogenate 11β-HSD2 activity, but similar umbilical
cord venous cortisone to cortisol ratio [45]. The reasons
underlying the lack of correlation between the venous
cord F/E ratio and placental 11β-HSD2 activity among
preterm and small for gestational age infants are unclear,
but might be explained by a greater contribution of pla-
cental 11β-HSD1 activity to circulating glucocorticoid lev-
els, or decreased glucocorticoid clearance by the placenta
or fetal tissues [45]. Our study included only infants born
later than 33 weeks gestation (mean 39.7 weeks), and the
majority of our participants were healthy term infants
with a birth weight appropriate for gestational age (mean
birth weight 3545 g), supporting the use of F/E as a valid
proxy for placental 11β-HSD2 activity in our study.
Strengths of our study include our adjustment for multi-
ple relevant confounders and careful blood pressure
measurements. Our study has several limitations. One
limitation is that we measured glucocorticoids only at a
single time point (delivery), and thus were unable to
measure the potential impact of presumed fetal glucocor-
ticoid exposure at earlier time windows during pregnancy.
By definition, use of a proxy for enzymatic activity results
in some misclassification of the exposure. A non-differen-
tial misclassification should have biased our findings
toward the null; therefore, our data may actually underes-
timate the association between fetal glucocorticoid expo-
sure and child BP. Our study did have some loss to follow-
up, and therefore may be subject to selection bias. How-BMC Medicine 2008, 6:25 http://www.biomedcentral.com/1741-7015/6/25
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ever, child BP among participants excluded from our anal-
yses was similar to those included in our analyses. It
seems unlikely that placental 11β-HSD2 activity would
systematically differ in participants excluded from our
analyses, although we cannot exclude this possibility.
Conclusion
In conclusion, our data show for the first time that a
higher F/E ratio in venous cord blood is associated with
higher offspring systolic blood pressure in humans. The
higher F/E ratio may reflect reduced placental 11β-HSD2
activity, resulting in increased fetal glucocorticoid expo-
sure and higher offspring systolic blood pressure. Our
study goes beyond previous data focusing on the birth
weight-blood pressure relationship to explore a potential
prenatal mechanism for the programming of later blood
pressure, but our findings are limited by the use of an
indirect measure of enzyme activity. Additional studies
using direct measures of enzymatic activity are needed to
definitively determine whether placental 11β-HSD2 activ-
ity does program blood pressure in childhood.
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